Johnson & Johnson targets $101.1 billion in 2026 sales after strong second quarter

Johnson & Johnson exceeded second-quarter expectations and elevated its full-year outlook, signalling confidence in sustained momentum. The healthcare conglomerate delivered adjusted earnings of $2.90 per share and generated $25.31 billion in quarterly revenue, both surpassing what Wall Street had projected. With this performance in hand, the company increased its 2026 sales target to $101.1 billion at the midpoint, a milestone that would mark the first time in the company's 140-year existence that it reaches the nine-figure revenue threshold. The improvement came despite headwinds from legacy products, most notably Stelara, which pressured overall growth. Oncology franchises including Darzalex, Carvykti, and Tecvayli fuelled expansion in its Innovative Medicine segment, while MedTech improved through wound closure, biosurgery, and electrophysiology offerings.

1. Adjusted per-share earnings of $2.90 in Q2 2026 climbed 4.7% year-over-year, beating the consensus estimate of $2.85
2. Second-quarter sales reached $25.31 billion, up 6.6% and exceeding the consensus projection of $25.05 billion
3. Operational sales expanded 5.6%, with adjusted operational sales growth at 5.7%
4. Full-year adjusted EPS guidance was raised to a $11.60-$11.75 range with $11.68 at midpoint, up from the previous $11.45-$11.65 range
5. Full-year 2026 reported sales guidance was raised to $101.1 billion at midpoint, reflecting 7.3% growth
6. Innovative Medicine sales advanced 6.8% on an operational basis while MedTech sales rose 3.6% operationally
7. Results were reported on July 15, 2026, with Stelara declines reducing overall growth by approximately 760 basis points